MediWound (MDWD)

MediWound’s lead commercial product is NexoBrid, an orphan biologic approved by the US Food and Drug Administration for eschar removal in adults with deep partial-thickness and full-thickness thermal burns. The treatment provides a non-surgical option for debriding severe burns and is intended to reduce reliance on excisional surgery, operating-room resources, and related complications in appropriate patients. NexoBrid is also marketed in international markets, including Europe, through commercial partnerships and regional arrangements.

The company’s pipeline extends its enzymatic debridement expertise into larger wound-care categories. EscharEx is being developed for the debridement of chronic and hard-to-heal wounds, a market that includes venous leg ulcers, diabetic foot ulcers, and pressure ulcers. MediWound is also advancing MW005, a topical product candidate being studied for non-melanoma skin cancers such as low-risk basal cell carcinoma.

Headquartered in Israel, MediWound operates as a specialised life sciences business with revenue primarily tied to the United States, alongside contributions from Europe and other international markets. Its investment profile is closely linked to adoption of NexoBrid, clinical progress across its wound-care pipeline, regulatory milestones, and the broader demand for alternatives to surgical debridement.